CeriBell (NASDAQ:CBLL) Price Target Raised to $33.00 at Canaccord Genuity Group

CeriBell (NASDAQ:CBLL) had its target price upped by Canaccord Genuity Group from $31.00 to $33.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued reports about the company. William Blair started coverage on CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. Bank of America assumed coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price for the company. Finally, TD Cowen initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $31.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $32.60.

CeriBell Trading Down 0.7 %

Shares of CBLL opened at $30.04 on Monday. CeriBell has a 12 month low of $23.00 and a 12 month high of $32.53.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $17.06 million. As a group, equities research analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.